Skip to main content
. 2021 Nov 15;145(3):184–193. doi: 10.1161/CIRCULATIONAHA.121.057812

Figure 3.

Figure 3.

Adjusted mean difference in KCCQ-CSS, TSS, OSS, and subdomains for empagliflozin versus placebo at 12, 32, and 52 weeks. CSS indicates Clinical Summary Score; empa, empagliflozin; KCCQ, Kansas City Cardiomyopathy Questionnaire; OSS, Overall Summary Score; and TSS, Total Symptom Score.